Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Azacitidine in Acute Myeloid Leukemia: NCT06754540 Clinical Landscape Report 2026
16 October 2026
NCT06754540 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tranexamic Acid in Sjogren's Syndrome: NCT06754371 Clinical Landscape Report 2026
16 October 2026
NCT06754371 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vispacabtagene regedleucel in Lupus Nephritis: NCT06752876 Clinical Landscape Report 2026
16 October 2026
NCT06752876 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BN-104 in Acute Myeloid Leukemia: NCT06746519 Clinical Landscape Report 2026
16 October 2026
NCT06746519 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RJK-RT2831 in Acute Myeloid Leukemia: NCT06756451 Clinical Landscape Report 2026
16 October 2026
NCT06756451 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Teclistamab in Multiple Myeloma: NCT06758375 Clinical Landscape Report 2026
16 October 2026
NCT06758375 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitoxantrone Hydrochloride liposomal in Acute Myeloid Leukemia: NCT06758726 Clinical Landscape Report 2026
16 October 2026
NCT06758726 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HR014(Hrain Biotechnology) in Relapsing acute myeloid leukemia: NCT06760260 Clinical Landscape Report 2026
16 October 2026
NCT06760260 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06765928 Clinical Landscape Report 2026
16 October 2026
NCT06765928 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-BCMA/FcRL5 CAR-T Cells(Xuzhou Medical University) in Relapse multiple myeloma: NCT06759181 Clinical Landscape Report 2026
16 October 2026
NCT06759181 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Enfortumab Vedotin-ejfv in Renal Pelvis and Ureter Urothelial Carcinoma: NCT06764095 Clinical Landscape Report 2026
16 October 2026
NCT06764095 clinical landscape for Renal Pelvis and Ureter Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
CD33 CAR-T(Zhejiang University) in Relapsing acute myeloid leukemia: NCT06762132 Clinical Landscape Report 2026
16 October 2026
NCT06762132 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…